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Abstract 28 
Introduction: To evaluate the impact of the pro-inflammatory cytokine hepatocyte growth 29 
factor (HGF) on the regulation of glucose and lipid placental metabolism. 30 
Methods: HGF levels were quantified in amniotic fluid and placenta from control and obese 31 
women. 2-deoxy-glucose (2-DOG) uptake, glycolysis, fatty acid oxidation (FAO), fatty acid 32 
esterification, de novo fatty acid synthesis, triglyceride levels and carnitine palmitoyltransferase 33 
activities (CPT) were measured in placental explants upon addition of pathophysiological HGF 34 
levels.  35 
Results: In obese women, total- and -activated-HGF levels in amniotic fluid were elevated 36 
~24%, and placental HGF levels were ~3-fold higher than in control women. At a similar dose to that 37 
present in amniotic fluid of obese women, HGF (30 ng/mL) increased Glut-1 levels and 2-DOG 38 
uptake by ~25-30% in placental explants. HGF-mediated effect on 2-DOG uptake was dependent on 39 
the activation of phosphatidylinositol 3-kinase signaling pathway. In addition, HGF decreased ~20% 40 
FAO, whereas esterification and de novo fatty acid synthesis increased ~15% and ~25% respectively, 41 
leading to 2-fold triglyceride accumulation in placental explants. In parallel, HGF reduced CPT-I 42 
activity ~70%.  43 
Discussion: HGF is a cytokine elevated in amniotic fluid and placental tissue of obese women, 44 
which through its ability to stimulate 2-DOG uptake and metabolism impairs FAO and enhances 45 
esterification and de novo fatty acid synthesis, leading to accumulation of placental triglycerides. 46 
 47 
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Introduction 50 
Obesity is a growing health concern in women of reproductive age because is associated with a 51 
broad range of maternal and fetal complications, such as macrosomia, a condition characterized by 52 
excessive fetal fat accretion that predispose the newborn to suffer metabolic diseases later in life [1-53 
4]. 54 
The mechanistic link between maternal obesity and fetal macrosomia is poorly understood. 55 
Maternal obesity is usually associated with hyperglycemia and hypertriglyceridemia, which may 56 
result in augmented transplacental nutrient transfer to the fetus. In the obesogenic-diabetogenic 57 
hypothesis proposed by Catalano et al. [2], changes in maternal availability of lipid surplus would 58 
facilitate non-esterified free fatty acids delivery to the adipocytes of the fetus, whereas maternal 59 
hyperglycemia and hyperinsulinemia would enhance lipogenesis leading to fetal adiposity. Hence, 60 
maternal hyperinsulinemia, and excessive circulating levels of glucose and lipids would play a direct 61 
role in the accumulation of fat in fetal adipose tissue. However, in pregnancies complicated with 62 
obesity, the expression of placental pro-inflammatory cytokines and certain immune cell populations 63 
are elevated leading to a chronic inflammatory milieu in which the fetus develops [5-7]. These 64 
observations have propelled the question whether excessive fetal adiposity can be explained solely as 65 
a result of higher circulating nutrients in maternal blood. Thus, it has been proposed that placental 66 
inflammation observed in obese women may modify the availability of nutrient supply at the 67 
maternal-fetal interface leading to augmented transplacental nutrient transfer to the fetus  [2]. 68 
Unfortunately, this question remains to be addressed, and the contribution of intrauterine pro-69 
inflammatory milieu on placental metabolism regulation has not been extensively investigated. 70 
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HGF is a pro-inflammatory cytokine elevated in serum of obese patients, which decline with 71 
weight loss and reduced body fat mass that occurs after gastroplasty [8-10]. The adipose tissue of 72 
these patients abnormally produces and secretes HGF, contributing to augmented serum HGF levels 73 
[9, 11]. HGF is activated by serine proteases, such as the HGF activator (HGFA), to exert its 74 
biological functions [12]. Although HGF was initially identified as a circulating factor that stimulates 75 
hepatocyte proliferation after liver injury [13], HGF exhibits pleiotropic biological functions in a 76 
broad range of cell types. Among them, HGF is a potent regulator of glucose and lipid metabolism in 77 
pancreatic β-cells, intestine epithelial cells, adipocytes and skeletal muscle cells [14]. 78 
HGF is also expressed in placental mesenchymal cells, syncytiotrophoblast cells of the chorionic 79 
villi and in amniotic epithelium cells [15]. The biological effects of HGF are mediated by its receptor 80 
(c-met) a transmembrane protein encoded by the MET proto-oncogene [16]. The receptor for HGF is 81 
primary localized in placental cytotrophoblast cells and to a lesser degree in syncytiotrophoblast cells 82 
[17]. In the literature, it can be found few and contradictory reports about plasma HGF levels during 83 
normal pregnancy and in pregnancies complicated with obesity. In normal pregnancy, HGF levels 84 
increased with gestational age until term [18, 19] or there was no change during pregnancy [20]. In 85 
pregnancies complicated with obesity, HGF levels were similar to normal women and remained 86 
unchanged with increasing BMI during the second trimester of pregnancy [21]. These results are in 87 
disagreement with the notion that in obese patients serum HGF associated with obesity [9, 11] and 88 
had a linear relationship with BMI [9]. Finally, total-HGF and activated-HGF blood levels in 89 
neonates are regulated in a time-dependent manner along fetal development [22]. 90 
In this study, we aimed to further understand the mechanistic link between maternal obesity, 91 
through its associated inflammatory uteroplacental environment, and the regulation of placental 92 
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metabolism. To this end, we tested the hypothesis that the pro-inflammatory cytokine HGF alters 93 
placental glucose and lipid metabolism leading to accumulation of placental triglycerides.  94 
Methods 95 
Study subjects 96 
The study was performed on placentas and amniotic fluid from pregnant women recruited at the 97 
Department of Obstetrics and Gynecology, University Hospital “Puerta del Mar” (HUPM). Patient 98 
samples were obtained after written informed consent in accordance with the HUPM Ethics 99 
Committee requirements and the Declaration of Helsinki. Specific exclusion criteria included women 100 
under the age of 18, smokers, a history of long-chain 3-hydroxyacyl-CoA deficiency, hemolysis 101 
elevated liver function syndrome or acute fatty liver of pregnancy, preeclampsia, chronic 102 
hypertension, pregestational diabetes, GDM, other co-morbid disease, abnormal karyotype, fetal 103 
malformations and multiple pregnancy. 104 
In the studies conducted using placental explants, pregnant women who planned to deliver by an 105 
elective Caesarean section due to clinical reasons such as breech presentation or prior Caesarean 106 
section were recruited. All Caesarean sections were performed at term. Placental samples and fasting 107 
maternal blood samples were obtained at the time of the elective Caesarean section. Neonatal 108 
anthropometric measurements were performed immediately at delivery as usual. In total, 26 women 109 
with no pregnancy complications (BMI 20-24.9) participated in the study for placental explants 110 
experiments. In addition, placentas from 10 obese women (pre-pregnancy BMI >30) were used in 111 
experiments showed in Figure 1. Randomly chosen subsets of placentas were used for the 112 
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experiments as indicated in the figure legends. In table 1 are listed demographics and baseline data, 113 
as well as perinatal variables. 114 
In the studies conducted using amniotic fluid, patients were eligible among pregnant women 115 
attending our antenatal clinic undergoing elective amniocentesis at 15-20 weeks of gestation for 116 
karyotype analysis, most of them due to advanced maternal age or combined screening showing high 117 
risk for trisomy 21. All fetuses were chromosomally and anatomically normal at delivery. Women 118 
were asked to give an extra amount of 3 mL of amniotic fluid for the study. Women were divided 119 
into two groups according to their pre-pregnancy BMI: the control group composed of 29 normal 120 
weight women (BMI 20-24.9); and the obese group, composed of 12 obese pregnant women (BMI 121 
>30). Demographics and baseline data, as well as perinatal variables, are shown in Table 2.  Specific 122 
exclusion criteria included women under the age of 18, smokers, a history of long-chain 3-123 
hydroxyacyl-CoA deficiency, hemolysis elevated liver function syndrome or acute fatty liver of 124 
pregnancy, preeclampsia, chronic hypertension, pregestational diabetes, GDM, other co-morbid 125 
disease, abnormal karyotype, fetal malformations and multiple pregnancy.  126 
Materials 127 
Cell culture reagents (RPMI-1640 medium without glucose) and fetal bovine serum were from 128 
Invitrogen/Gibco, California, USA. The [9,10-
3
H]-palmitic acid, [
3
H]-H2O,  2-[1,2-
3
H]-deoxy-D-129 
glucose, [1-
14
C]-mannitol, [5-
3
H]-glucose, [1,2-
14
C]-acetic acid, L-[N-methyl-
14
C]-carnitine-HCl and 130 
liquid scintillation counting cocktail were from PerkinElmer, Massachusetts, USA. Methotrexate, 131 
Wortmannin, 2-deoxy-glucose (2-DOG) and cytochalasin B were purchased from Sigma-Aldrich 132 
(Madrid, Spain). Recombinant human HGF was purchased from Millipore Iberica (Madrid, Spain). 133 
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Biochemical parameters and HGF determination 134 
All biochemical parameters were analyzed at the clinical laboratory, HUPM, using reagents and 135 
modular systems from Roche Diagnostics as described previously [23]. Low-density lipoprotein 136 
cholesterol (LDL-c) was calculated using the Friedewald-Fredrickson formula.  137 
Human total-HGF (t-HGF) and activated-HGF (a-HGF) were measured by ELISA using a 138 
commercially available kit supply by IBL International GmbH (Hamburg, Germany). Each assay 139 
required 100 µL of amniotic fluid to determine the levels of t-HGF and a-HGF. 140 
Placental explants culture 141 
Term placenta obtained from elective Caesarean section was placed on ice and arrived to the 142 
laboratory within 10-15 minutes of delivery. Afterwards, placental villous explants (~100 mg wet 143 
weight) were dissected and cultured in 6-well plate containing 2 mL of culture medium (RPMI-1640 144 
supplemented with 5 mmol/l glucose, 10% FBS (vol/vol), 100 units/ml penicillin G, and 100 µg/ml 145 
streptomycin) as described previously [23].  146 
Fatty acid oxidation assay 147 
Stock of fatty acid solution was prepared by conjugating palmitate with essentially fatty acid-free 148 
bovine serum albumin (BSA) to generate a stock solution of 25% (wt/vol) BSA, 4 mmol/L palmitate 149 
in culture medium were prepared as described previously [23]. Mitochondrial fatty acid oxidation 150 
(FAO) assays were performed in placental explants as described previously [23-25]. Briefly, freshly 151 
isolated villous explants were incubated in culture media in the presence or absence of HGF, plus 152 
1.25% BSA, 0.1 mmol/l cold palmitate, and 18500 Bq/ml [
3
H]-palmitate at 37ºC for 18h. At the end 153 
of the incubation period, the medium was  collected, and tritiated water determined by the vapor-154 
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phase equilibration method of Hughes et al [26]. FAO was defined as nmol of palmitate per mg of 155 
tissue per hour.  156 
Esterification into total lipids assay 157 
Incorporation of [
3
H]-palmitate into total lipids was determined as previously described [23, 24]. 158 
Briefly, after similar incubation conditions to those used for measurements of β-oxidation, in the 159 
presence or absence of HGF, plus 0.1 mmol/L cold palmitate and 18500 Bq/mL for 18h, explants 160 
were washed 3 times with 2 mL of ice-cold PBS and homogenized in 500 µL of PBS. An aliquot of 161 
100 µL was used to extract the lipid content from samples according to Bligh and Dyer [27]. 162 
Afterwards, the radioactive content was determined by liquid scintillation counting. Esterification 163 
was plotted as % of control. 164 
De novo lipid synthesis assay 165 
De novo lipid synthesis was determined using [
14
C]-acetate in placental explants according to the 166 
procedure described previously [23, 24]. Villous placental explants were incubated in RPMI-1640 167 
culture media in the presence or absence of HGF plus 1850 Bq/mL [
14
C]-acetate at 37ºC for 18h. At 168 
the end of the incubation period, culture media were discarded followed by tissue homogenization in 169 
500 µL of PBS. After a total lipid extraction (as described for measurements of placental 170 
esterification rate), the radioactive content was determined.  171 
Glycolysis assay 172 
Glucose utilization (equivalent to glycolysis) was determined as the production of tritiated water 173 
(as for FAO experiments) after incubation of placental explants for 18h in the presence or absence of 174 
HGF, plus 240500 Bq/mL [5-
3
H]-glucose [24, 28].  175 
9 
 
 
 
 
 
Glucose transport assay 176 
Uptake of [
3
H]-2-DOG was performed ex vivo in placental explants, as described previously 177 
[14], with the following modifications. Freshly isolated placental explants were preincubated for 18h 178 
in culture medium in the presence or absence of HGF, plus cytochalasin B, a potent inhibitor of 179 
glucose transport mediated via facilitative glucose transporters. Afterwards, explants were washed in 180 
transport solution buffer (20 mmol/L Hepes-Na pH 7.4, 140 mmol/L NaCl, 5 mmol/L KCl, 2.5 181 
mmol/L MgSO4, 1 mol/L CaCl2 ) at room temperature, and  immediately incubated in transport 182 
solution buffer plus 10 µmol/L 2-DOG (18500 Bq/mL [
3
H]-2-DOG) and 39 mmol/L mannitol 183 
(11840 Bq/mL [
14
C]-mannitol) with or without HGF for 1 min. Then, explants were removed 184 
rapidly, rinsed with cold 0,9% NaCl to stop reactions, blotted, digested in 1 mol/L NaOH and 185 
analyzed for 
14
C and 
3
H content.  Glucose uptake was defined as nmol of 2-DOG per mg of protein 186 
per minute. 187 
Quantification of triglyceride content 188 
Placental triglyceride content was determined, as previously described by Perdomo et al. [29], in 189 
explants preincubated in the presence or absence of HGF for 18h.  Placental tissues (~100 mg) were 190 
homogenized in 400 µl HPLC-grade acetone, and aliquots of 5 µl of acetone-extracted lipid 191 
suspension were used to determined triglyceride concentrations using a triglyceride reagent kit 192 
(Biosystems, Barcelona, Spain). Proteins were quantified using the bicinchoninic acid method 193 
(Thermo Scientific, Madrid, Spain). Placental lipid content was defined as mg of triglyceride per mg 194 
of total placental proteins. 195 
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Western blot analysis 196 
Placental explants from control and obese women were dissected and washed with ice-cold PBS, 197 
followed by homogenization in lysis buffer (20 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1 mmol/l 198 
EDTA, 1 mmol/l EGTA, 1% (v/v) Triton X-100, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l β-199 
glycerophosphate, 1 mmol/l Na3VO4, 1 µg/ml leupeptin, 1 mmol/l phenylmethylsulfonyl fluoride) ) 200 
plus protease inhibitors (Protease Inhibitor Cocktail, Sigma, St. Louis, MO). After 10 min. on ice, 201 
extracts were sonicated and centrifugated at 18,000 X g for 10 minutes at 4ºC. Pellets were discarded 202 
and solubilized proteins (40-60 µg/sample) were resolved by 10% SDS-PAGE for HGF and 203 
electrotransferred onto polyvinylidene difluoride (PVDF) filters for immunoblotting by conventional 204 
means. After probing with specific antibodies [glucose transporter 1 (Glut-1; 1:2000, Abcam, 205 
Cambridge, UK) HGF antibody (1:1000, Santa Cruz Biotechnology, Inc., Heidelberg, Germany) and 206 
protein kinase B (PKB; 1:1000, Cell Signaling, Barcelona, Spain)], the membranes were stripped and 207 
reprobed against phospho-PKB at Ser473 (p-PKB; 1:1000, Cell Signaling, Barcelona, Spain), or 208 
actin (1:3000, Sigma, Madrid, Spain). Signals were detected by chemiluminiescence (Immun-Start 209 
western chemiluminiescence kit, Bio-Rad, Madrid, Spain), and band densitometry was quantified 210 
with the ImageJ software (NIH, USA). 211 
CPT assay 212 
Activities of carnitine palmitoyltransferase I (CPT-I) and carnitine palmitoyltransferase II (CPT-213 
II) were determined in the direction of acyl-carnitine formation, using [
14
C]-carnitine as substrate in 214 
placental explants as described previously [23, 25, 30]. Briefly, explants were preincubated in RPMI-215 
1640 culture media in the presence or absence of HGF (30 ng/mL) at 37ºC for 18h. At the end of the 216 
incubation period, culture media were discarded, and explants were washed with ice-cold PBS prior 217 
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to homogenization in lysis buffer (5 mmol/l Tris-HCl, pH 7.2, 150 mmol/l KCl) with a glass 218 
homogenizer. For CPT-I assay, 100 µl of cell homogenate, in which the mitochondria remain largely 219 
intact, was incubated in the presence of 50 µmol/l palmitoyl-CoA, 500 µmol/l carnitine, and 220 
9250Bq/ml [
14
C]-carnitine in a 30ºC shaking water bath for 10 min. For CPT-II assay, a portion of 221 
the homogenate was adjusted to 1 % (wt/v) of the detergent octylglucoside, which solubilizes the 222 
mitochondrial membranes, inactivating CPT-I and releasing CPT-II from the mitochondrial matrix in 223 
active form. Afterward, reactions were stopped by adding 500 µl of 1-butanol. Radioactive content 224 
was determined by liquid scintillation counting. 225 
Statistical analysis 226 
Statistical analysis of data was performed using the SPSS software (SPSS 20.0, Inc., Chicago, 227 
IL). Data were presented as mean ± SEM. Distributions were checked with a histogram and the 228 
Kolmogorov-Smirnov test. Comparisons between two groups were done by unpaired Student´s t-test, 229 
and comparisons between more than two groups were performed by ANOVA followed by Tukey's 230 
Multiple Comparison Test. Differences were considered significant at p<0.05.” 231 
Results 232 
HGF is elevated in amniotic fluid and placenta from obese pregnant women 233 
Obesity in pregnancy induces placental inflammation, which is associated with production of 234 
pro-inflammatory mediators [5]. To determine the presence of the pro-inflammatory cytokine HGF 235 
in the inflammatory milieu, in which the fetus develop, we measured t-HGF and a-HGF levels in 236 
amniotic fluid from control and obese pregnant women during early- mid pregnancy. As shown in 237 
Figure 1A-B, t-HGF and a-HGF are elevated up to ~30 ng/mL in amniotic fluid from obese women. 238 
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In addition, HGF levels in placentas from obese women were ~3-fold higher than in control women 239 
(Fig. 1C).  240 
HGF increases glucose transport and metabolism in human placental explants 241 
HGF is a potent stimulator of glucose transport and metabolism in different cell types [14]. 242 
Because HGF is elevated in placental explants and amniotic fluid from obese women, we 243 
hypothesized that HGF stimulates glucose uptake in human placenta. To test our hypothesis, we 244 
preincubated placental explants, from pregnancies without complications, in the presence or absence 245 
of HGF for 18h, and measured glucose transport and glycolysis. HGF significantly increased 2-DOG 246 
uptake in human placental explants and the effect was maximal (~30%) at 30 ng/mL (Fig. 2A). 247 
Interestingly, in the presence of 10µM cytochalasin B (CB; an inhibitor of facilitative glucose 248 
transport), 2-DOG uptake was suppressed by ~60%, whereas in the presence of 50µM CB B by 249 
~90% (Fig. 2B). Likewise, CB completely abolished the effect of HGF on 2-DOG uptake, suggesting 250 
that HGF-mediated 2-DOG uptake in human placental explants was likely mediated by a facilitative 251 
glucose transport (Fig. 2B).   Finally, HGF-mediated effect on 2-DOG uptake was accompanied by a 252 
significant augment (~20%) on glycolysis in placental explants (Fig. 2C). Collectively, these results 253 
demonstrate a novel role of HGF in the regulation of placental glucose metabolism. 254 
HGF-mediated glucose uptake in human placental explants is Glut-1 and phosphatidylinositol 255 
3-kinase (PI3K) dependent 256 
Glucose transport is mainly regulated by Glut-1 in human placenta [31]. Consequently, we 257 
hypothesized that pathophysiological levels of HGF stimulates glucose uptake in human placental 258 
explants through up-regulation of Glut-1. To test this hypothesis, we analyzed Glut-1 levels in 259 
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protein extracts prepared from explants after chronic exposure to HGF for 18h. As shown in Figure 260 
3A, treatment with HGF increased by ~25% Glut-1 levels.  261 
To gain further insight into the molecular mechanism by which HGF regulates glucose transport 262 
and Glut-1 levels, we analyzed the possible signaling pathways downstream of c-met in placental 263 
explants. To this end, explants were preincubated in the presence or absence of HGF (30 ng/mL) in a 264 
time dependent manner (from 0 to 60 min), and PI3K signaling pathway was studied by immunoblot 265 
analysis. HGF potently and rapidly stimulated PKB phosphorylation in a time-dependent manner 266 
(Fig. 3B).  To reveal whether the inhibition of this signaling pathway could reverse the effect of HGF 267 
on glucose transport, we preincubated placental explants with 100 nM wortmannin (WM; a PI3K 268 
inhibitor) for 30 min before and during chronic (18h) incubation with HGF (30ng/mL). At the end of 269 
the incubation period, the 2-DOG uptake was measured in these cells. As shown in Figure 3C, 270 
wortmannin completely abolish the effect of HGF on glucose transport. Taken together, these results 271 
indicate that PI3K signaling pathway is involved in HGF-mediated 2-DOG uptake in human 272 
placental explants.  273 
HGF alters the metabolic partitioning of fatty acids in human placental explants 274 
We showed above that HGF enhanced glucose transport and utilization in placental explants. 275 
Therefore, it is reasonable to hypothesize that HGF-mediated accelerated glucose metabolism would 276 
inhibit fatty acid oxidation leading to accumulation of placental triglycerides. To test this hypothesis 277 
we measured the effect of chronic exposure (18h) to pathophysiological levels of HGF (30 ng/mL) 278 
on FAO in placental explants. As shown in Figure 4A, HGF significantly reduced the FAO rate by 279 
~20% in placental explants. In parallel, HGF enhanced fatty acid esterification by ~15% (Fig. 4B). 280 
Surprisingly, HGF also augmented de novo fatty acid synthesis by ~25% (Fig. 4C). Finally, 281 
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consistently with the expectation that fatty acids are preferentially directed towards esterification, 282 
and that HGF stimulated de novo fatty acid synthesis, placental triglyceride content significantly 283 
increased 2-fold in placental explants (Fig. 4D). Taken together, these data indicate that HGF alters 284 
the metabolic partitioning of fatty acids towards triglyceride accumulation through inhibition of FAO 285 
and stimulation of esterification and de novo fatty acid synthesis. 286 
HGF decreases carnitine palmitoyltransferase I activity in human placental explants 287 
Because HGF increased glucose transport and utilization, in parallel with diminished FAO, we 288 
hypothesized that the mechanistic link between accelerated glucose metabolism and lower FAO was 289 
inhibition of CPT-I activity by its physiological inhibitor malonyl-CoA, which is synthesized from 290 
glucose-derived acetyl-CoA by acetyl-CoA carboxylase (ACC) activity. Therefore, to gain further 291 
insight into the molecular mechanism by which HGF inhibits FAO in placental explants, we 292 
measured the activity of CPT-I and CPT-II in placental explants preincubated without (control) or 293 
with HGF (30 ng/mL) for 18h. As shown in Figure 7, HGF reduced by ~70% the activity of CPT-I 294 
(Fig. 5A), whereas CPT-II activity remained unchanged as expected (Fig. 5B).  295 
Discussion 296 
In obese women, the risk of macrosomia is 2-fold higher than in control women [2], leading to 297 
heavier neonates because of an increase in fat but not lean body mass [32]. Excessive fat 298 
accumulation in adipose tissue of newborns predispose them to suffer from metabolic diseases later 299 
in life [4], which perpetuates a vicious cycle of obesity and diabetes. At first glance, 300 
hypertriglyceridemia in plasma from obese women, secondary to maternal insulin resistance, would 301 
facilitate non-esterified free fatty acids delivery to the adipocytes of the fetus through potential 302 
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mechanisms such as alteration of concentration gradients across the placental barrier, and changes in 303 
the levels and/or activity of lipoprotein lipase, fatty acid-binding proteins and fatty acid transporters 304 
in syncytiotrophoblast cells [33]. Thus, it has been shown that maternal obesity modulates placental 305 
fatty acid transporters and placental fatty acid transport and metabolism [34, 35].  306 
Maternal obesity during pregnancy is also associated with placental accumulation of immune 307 
cells, such as macrophages and neutrophils, lipid accumulation in the placental villi stroma and 308 
syncytium, and elevated pro-inflammatory cytokines leading to lipotoxicity and inflammation [5-7, 309 
33, 36]. In this work, we showed that HGF is elevated in placental tissue and amniotic fluid of obese 310 
women during early- mid pregnancy, and identified mechanisms by which HGF regulated placental 311 
lipid accumulation. However, the molecular and biochemical mechanisms by which obesity is related 312 
to enhance pro-inflammatory cytokines expression in placenta have not been entirely clarified. A 313 
conceivable mechanism by which placental HGF production is augmented could be related to the 314 
lipotoxic and pro-inflammatory placental environment. Excessive circulating maternal free fatty 315 
acids and/or elevated glucose levels, which reduce fatty acid oxidation and enhance esterification 316 
through inhibition of carnitine palmitoyltransferase I [23], would lead to the accumulation of 317 
triglycerides in placenta. This accumulation of lipids may trigger activation of toll-like receptors 318 
(TLR) in trophoblast and/or macrophages, which would signal through phosphorylation of the c-Jun 319 
N-terminal kinase (JNK) and the inhibitor of κB  (IκB), leading to activation of the nuclear factor-kB 320 
(NF-κB) and activator protein 1 (AP-1), the primary mediators of inflammatory responses. This 321 
signaling pathway could be further stimulated by interleukin 1-beta (IL-1β), tumor necrosis alpha 322 
(TNF-α) and interleukin 6 (IL-6), constituting a vicious cycle. Nonetheless, signaling pathways 323 
involved in the production/ secretion of HGF in placentas from obese women remains unknown. 324 
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Using placental explants from women with no pregnancy complications, we demonstrate that at 325 
similar concentration to that present in amniotic fluid of obese women during early- mid pregnancy, 326 
HGF inhibited FAO and increased triglyceride accumulation. A limitation of this study is that we 327 
performed a cross-sectional study regarding HGF levels in amniotic fluid. Thus, in the absence of a 328 
longitudinal study, we cannot assume that HGF levels during the third trimester are similar to those 329 
measured during the second trimester. Nonetheless, these HGF levels augmented Glut-1 protein 330 
levels, glucose transport and metabolism. We evaluated whether the mechanistic link between HGF 331 
and lower FAO was inhibition of CPT-I activity by its physiological inhibitor malonyl-CoA, which 332 
is synthetized from glucose-derived acetyl-CoA by ACC.  This mechanism results in a shift of fatty 333 
acid partitioning away from the β-oxidation pathway toward esterification, allowing the 334 
accumulation of triglycerides in placenta. This notion is in agreement with our findings in placentas 335 
from pregnancies complicated by GDM, where we showed that accelerated glucose metabolism in 336 
placental explants lowered FAO [23]. The impact of other pro-inflammatory cytokines on lipid 337 
metabolism has not been extensively studied. In human trophoblast cell cultures IL-6, but not TNF-α, 338 
stimulated fatty acid accumulation [37]. This effect was not explained by an increased expression of 339 
lipoprotein lipase or fatty acid binding proteins. Although the mechanism by which IL-6 stimulates 340 
trophoblast fatty acid accumulation remains to be established, it is plausible to hypothesize that 341 
would be mediated by inhibition of FAO and/or stimulation of de novo fatty acid synthesis. Finally, 342 
this knowledge about HGF-mediated accelerated glucose metabolism and its impact on placental 343 
lipid metabolism, may offer new therapeutic targets for clinical management of pregnancies 344 
complicated by obesity. 345 
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Earlier studies suggested that de novo fatty acid synthesis pathway plays a minor role on 346 
accumulation of triglycerides in placentas from pregnancies complicated with diabetes [23, 38]. 347 
However, we demonstrated that HGF stimulated de novo fatty acid synthesis in placental explants 348 
from women with no pregnancy complication. If this HGF-mediated regulation on fatty acid 349 
synthesis would translate directly into the in vivo situation of placentas from obese women, the 350 
glucose-derived malonyl-CoA, synthesized by the activity of ACC, would not merely serve as a 351 
regulator of FAO pathway; but in addition, it would serve as a regulator of the de novo fatty acid 352 
synthesis. Consequently, de novo fatty acid synthesis pathway in placenta from pregnancies 353 
complicated with obesity would significantly contribute to placental triglycerides accumulation and 354 
augmented transplacental fatty acids delivery to fetal adipocytes.  355 
Although it is known that HGF participates in the regulation of glucose transport in different 356 
cells types [14], no study has addressed weather HGF might regulate glucose metabolism in human 357 
placenta. The current study demonstrates for the first time that HGF increases glucose uptake and 358 
utilization in human placental explants ex vivo. Our studies establish that, in addition to behaving as 359 
a growth factor, HGF has additional biological features as a modulator of glucose metabolic flux in 360 
placental cells engaged in glucose homeostasis control. Interestingly, HGF significantly increased 361 
total Glut-1 expression in human placental explants, which is associated with augmented glucose 362 
uptake. Furthermore, inactivation of PI3K signaling pathway completely abolished HGF-mediated 363 
effect on glucose uptake. We have previously showed that HGF also activates PI3K and ERK1/2 364 
signaling pathways in parallel with up-regulation of Glut-1 levels in skeletal muscle cells [14]. 365 
Likewise, pharmacological inhibition of these pathways also abolished glucose uptake in these cells 366 
[14]. Also, Di Simone et al. showed that resistin, a cytokine elevated in serum of third trimester 367 
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normal pregnancies, stimulated glucose uptake and Glut-1 levels in trophoblast cells through 368 
activation of ERK1/2 pathway [39]. Collectively, these results highlight an underappreciated role for 369 
cytokines in the control of glucose transport and metabolism in human placenta. 370 
In conclusion, HGF is a mechanistic link between the intrauterine pro-inflammatory milieu of 371 
pregnancies complicated with obesity and its associated placental lipotoxicity. Because most of 372 
maternal cytokines do not cross the human placental barrier, we propose that synthesized HGF 373 
within the placenta itself exacerbates lipotoxicity through biochemical mechanisms involving 374 
augmented glucose transport, fatty acid esterification and de novo fatty acid synthesis, which lead to 375 
placental triglyceride accumulation.  Finally, our results suggest that placental inflammation may 376 
play an indirect role on fetal macrosomia modifying the availability of nutrient supply to the fetus. 377 
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Figure legends 489 
Figure 1. HGF levels in amniotic fluid and placentas from obese pregnant women. HGF 490 
levels in amniotic fluid. t-HGF (A) and a-HGF (B) were measured in amniotic fluid from control 491 
(n=29) and obese (n=12) women by ELISA (see details in Table 2). Values are means ± SEM.  492 
*p<0.05 relative to control group by unpaired t-test. (C) Western blot analysis of HGF in placental 493 
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tissue from control and obese women. Frozen placental tissues (~100 mg) from control (n=8) and 494 
obese (n=10) groups (see details in Table 1) were used to quantify placental HGF content. β-actin 495 
expression was determined to ensure similar protein loading. Top: the y-axis represents the ratio of 496 
HGF vs. β-actin in arbitrary units (A.U). Bottom: a representative picture of the western blot is 497 
shown. Data are means ± SEM.*p<0.05 relative to control group by unpaired t-test.  498 
Figure 2. HGF stimulates glucose uptake and metabolism in human placental explants. (A) 499 
Stimulation of glucose uptake in placental explants. Placental explants from control women (n=3; 500 
Table 1) were incubated with different concentrations of HGF for 18h, and 2-DOG uptake was 501 
measured. Values are means ± SEM for 3 independent experiments in triplicate. *p<0.05 relative to 502 
control without HGF by ANOVA. (B) Effect of cytochalasin B (CB) on 2-DOG uptake mediated by 503 
HGF. Placental explants from control women (n= 4; Table 1) were treated with HGF (30 ng/ml) for 504 
18h in the presence or the absence of CB at 10 µM or 50 µM. Afterward, 2-DOG uptake was 505 
determined. Values are means± SEM for 4 independent experiments in triplicate. *p<0.05 relative to 506 
control without CB and without HGF; 
†
p<0.05 relative to HGF without CB by ANOVA. (C) Effect 507 
of HGF on glycolysis in placental explants. Placental explants from control women (n=7; Table 1) 508 
were treated with HGF (30ng/ml) for 18h. Afterward, glycolysis was determined. Values are 509 
represented as percentage of control for 7 independent experiments in triplicate. *p<0.05 relative to 510 
control by unpaired t-test. 511 
Figure 3. Augmented Glut-1 protein levels and activation of PI3K signaling pathway are 512 
required for HGF-mediated stimulation of glucose transport in human placental explants. (A) 513 
Western blot analysis of Glut-1 in placental explants. Explants from control women (n=4; Table 1) 514 
were preincubated with or without HGF (30 ng/mL) for 18h, and protein extracts were subjected to 515 
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immunoblot analysis using anti-Glut-1 antibody. Top: the y-axis represents the ratio of Glut-1 vs. β-516 
actin in arbitrary units (A.U). Bottom: a representative picture of the western blot is shown. Data are 517 
means ± SEM for 4 independent experiments. *p<0.05 relative to control by unpaired t-test. (B) 518 
Western blot analysis of PI3K-signaling pathway activation mediated by HGF in placental explants. 519 
Explants from control women (n=4; Table 1) were preincubated without (time 0) or with HGF 520 
(30ng/mL) for the indicated times. Afterward, protein extracts were subjected to immunoblot 521 
analysis using anti-PKB or anti-p-PKB antibody. Top: the y-axis represents the ratio of p-PKB vs. 522 
PKB in arbitrary units (A.U). Bottom: a representative picture of the western blot is shown. Data are 523 
means ± SEM for 4 independent experiments. *p<0.05 relative to time 0 by ANOVA. (C) Effect of 524 
wortmannin-mediated inhibition of PI3K signaling pathway on 2-DOG uptake. Placental explants 525 
from control women (n=4; Table 1) were preincubated with 100 nmol/L wortmannin (WM) for 30 526 
min before and during chronic (18h) incubation with HGF (30 ng/mL). At the end of the incubation 527 
period, the 2-DOG uptake was measured. Values are means ± SEM for 4 independent experiments in 528 
triplicate. *p<0.05 relative to control without HGF; 
†
p<0.05 relative to HGF without WM by 529 
ANOVA.  530 
Figure 4. HGF inhibits fatty acid oxidation and increases triglycerides content in human 531 
placental explants. (A) Effect of HGF on fatty acid oxidation. Placental explants from control 532 
women (n=7; Table 1) were incubated in the absence (control) or presence of HGF (30 ng/mL) for 533 
18h. Afterward, [
3
H]-water was determined. Values are means ± SEM for 7 independent experiments 534 
in triplicate. Significance is indicated *p<0.05 relative to control by unpaired t-test.  (B) Effect of 535 
HGF on fatty acid esterification. The same subset of placental explants described in panel A was 536 
used to assess esterification into total lipids. Values are represented as percentage of control for 7 537 
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independent experiments in triplicate. Significance is indicated *p<0.05 relative to control by 538 
unpaired t-test. (C) Effect of HGF on de novo lipid synthesis. Placental explants from control women 539 
(n=7; Table 1) were used to assess de novo fatty acid synthesis in the absence (control) or presence 540 
of HGF (30 ng/mL) plus [
14
C]-acetate for 18h. Afterward, [
14
C]-acetate incorporation into total lipids 541 
was determined. Values are represented as percentage of control for 7 independent experiments in 542 
triplicate. Significance is indicated *p<0.05 relative to control by unpaired t-test. (D) Placental 543 
explants from control women (n=4; Table 1) were used to assess the effect of HGF on placental TG 544 
accumulation. Values are means ± SEM for 4 independent experiments in triplicate. Significance is 545 
indicated *p<0.05 relative to control by unpaired t-test. 546 
Figure 5. HGF inhibits carnitine palmitoyltransferase I activity. (A) Effect of HGF on CPT-I 547 
activity. Placental explants from control women (n=4; Table 1) were incubated in the absence 548 
(control) or presence of HGF (30ng/mL) for 18h. Afterward, CPT-I activity was determined. Values 549 
are means ± SEM for 4 independent experiments in duplicated. Significance is indicated *p<0.05 550 
relative to control by unpaired t-test. (B) Effect of HGF on CPT-II activity. The same placental 551 
explants used in panel A were used to assess CPT-II activity. Values are means ± SEM for 4 552 
independent experiments in duplicated. Significance is indicated *p<0.05 relative to control by 553 
unpaired t-test.  554 
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Table 1. Placental explants samples. Maternal and fetal characteristics from 
the studied population used for placental explants experiments. 
 
 Control group (n=26) Obese group (n=10) 
Delivery mode 
Caesarean section 
No labour 
Caesarean section 
No labour 
Maternal age (yr) 30.0 ± 5.7 31.8 ± 4.0 
Gestational age at delivery (wk) 38.3 ± 1.81 38.6 ± 0.9 
Maternal pregravid BMI (kg/m2) 21.4 ± 1.5 34.2 ± 4.1* 
Maternal plasma glucose (mg/dL) 72.8 ± 6.6 80.6 ± 15.3 
Maternal plasma insulin (pmol/L) 6.5 ± 3.7 16.1 ± 9.4* 
Maternal plasma triglycerides (mg/dL) 182.0 ± 35.8 226.5 ± 48.6 
Maternal plasma total cholesterol (mg/dL) 249.8 ± 32.0 288.4 ± 35.1* 
Maternal plasma HDL-cholesterol (mg/dL) 73.3 ± 21.2 68.0 ± 18.0 
Maternal plasma LDL-cholesterol (mg/dL) 144.9 ± 24.3 158.7 ± 40.5 
Placental weight (g) 528 ± 106 617 ± 42* 
Birthweight (g) 3225 ± 309 3235 ± 279 
 
Data are given as mean ± SEM. BMI, Body mass index;  HDL, High-density 
lipoprotein; LDL, Low-density lipoprotein. *p<0.05 vs. control group by unpaired 
t-test.  
 
Table-1
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Table 2. Amniotic fluid samples. Maternal and fetal characteristics from the studied 
population used for amniotic fluid collection. 
 Control  group (n=29) Obese group (n=12) 
Maternal age (yr) 35.61 ± 5.02 35 ± 1.1 
Gestational age at amniocentesis (wk) 16 (15-17) 16 (16-17) 
Gestational age at delivery (wk) 40.0 ± 1 39 ± 1.7 
Body mass index (kg/m2) 22.69 ± 1.3 34.6 ± 2.56* 
Newborn weight (g) 3258.52 ± 475 3357 ± 579 
 
Data are given as mean ± SE. Gestational age at amniocentesis is listed as median 
(interquartile range).  *p<0.05 vs. control group by unpaired t-test.  
Table-2
Click here to download Table: Table-2-Placenta-3rd submition.doc
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